Clinical Report: Single-Cell Sequencing Uncovers Malignant Skin-Restricted Phenotypes in PTCL-NOS
Overview
This report presents a case study of a 67-year-old male with PTCL-NOS and cutaneous involvement, highlighting the aggressive nature of the disease and poor response to treatment. Single-cell RNA sequencing revealed distinct malignant T-cell phenotypes in skin lesions compared to peripheral blood, providing insights into the tumor microenvironment's role in disease progression.
Background
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous and aggressive subtype of non-Hodgkin lymphoma, accounting for 15-20% of lymphoid neoplasms. The presence of cutaneous involvement often indicates a poor prognosis, with limited treatment options and high rates of treatment resistance. Understanding the molecular mechanisms driving this aggressive behavior is crucial for developing targeted therapies.
Data Highlights
No numerical data or trial data presented in the article.
Key Findings
Single-cell RNA sequencing revealed hyperproliferative malignant T cells in skin lesions with activation of NF-κB and IL-17 signaling.
Copy number variation analysis confirmed clonal expansion in both skin and blood compartments.
The patient experienced primary refractory disease despite multiple chemotherapy regimens.
This case is the first to report a single-cell transcriptomic comparison of skin and blood in PTCL-NOS.
Clinical Implications
The findings underscore the importance of understanding the tumor microenvironment in PTCL-NOS, particularly in cases with cutaneous involvement. Targeting specific pathways identified in malignant T cells may offer new therapeutic strategies for improving patient outcomes.
Conclusion
This case study highlights the aggressive nature of PTCL-NOS with cutaneous involvement and the potential for single-cell sequencing to inform targeted treatment approaches. Further research is needed to explore compartment-specific therapies based on these findings.
Lung cancer resulted in 1.8 million deaths globally in 2022 and remains the leading cause of cancer-related mortality worldwide. Low-dose CT screening has been shown to reduce lung cancer mortality, a...
The National Comprehensive Cancer Network® (NCCN®) first introduced the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, initially covering eight tumor types. Three decades la...
With recent data that RAS inhibition can improve survival in metastatic pancreatic cancer, the optimization of these agents has become a research priority. Minh Than, MD, PhD, a clinical and research ...
